Product Description:

• NUCALA is indicated for the:
• treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
• treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

How to use:

• Once-monthly dosing (every 4 weeks)
• No loading dose
• Fixed dose (independent of weight)

Caution & Warnings:

• Hypersensitivity Reactions
• Acute Asthma Symptoms or Deteriorating Disease
• Opportunistic Infections: Herpes Zoster
• Reduction of Corticosteroid Dosage
• Parasitic (Helminth) Infection

ADVERSE REACTIONS:

• In clinical trials in patients with severe asthma (100 mg of NUCALA), the most common adverse reactions (≥5%) were headache, injection site reaction, back pain, and fatigue.
• In clinical trials in patients with HES (300 mg of NUCALA), no additional adverse reactions were identified to those reported in severe asthma clinical trials. Systemic reactions, including hypersensitivity, also occurred. The manifestation reported was multifocal skin reaction, experienced on the day of dosing.

Ingredients:

• Mepolizumab 100mg.